197 related articles for article (PubMed ID: 24971661)
1. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
Padhi D; Higano CS; Shore ND; Sieber P; Rasmussen E; Smith MR
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1967-75. PubMed ID: 24971661
[TBL] [Abstract][Full Text] [Related]
2. Myostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia?
Grossmann M
J Clin Endocrinol Metab; 2014 Oct; 99(10):3625-8. PubMed ID: 25279574
[No Abstract] [Full Text] [Related]
3. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
4. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
6. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
7. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy.
Uth J; Hornstrup T; Schmidt JF; Christensen JF; Frandsen C; Christensen KB; Helge EW; Brasso K; Rørth M; Midtgaard J; Krustrup P
Scand J Med Sci Sports; 2014 Aug; 24 Suppl 1():105-12. PubMed ID: 24944134
[TBL] [Abstract][Full Text] [Related]
8. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
9. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty.
Woodhouse L; Gandhi R; Warden SJ; Poiraudeau S; Myers SL; Benson CT; Hu L; Ahmad QI; Linnemeier P; Gomez EV; Benichou O;
J Frailty Aging; 2016; 5(1):62-70. PubMed ID: 26980371
[TBL] [Abstract][Full Text] [Related]
11. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia during androgen-deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Sieber PR; Tammela TL; Ke C; Leder BZ; Goessl C
J Clin Oncol; 2012 Sep; 30(26):3271-6. PubMed ID: 22649143
[TBL] [Abstract][Full Text] [Related]
13. The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome.
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A
Endocrine; 2015 Sep; 50(1):223-30. PubMed ID: 25588772
[TBL] [Abstract][Full Text] [Related]
14. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
15. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
Smith MR
Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
[TBL] [Abstract][Full Text] [Related]
16. Changes in body composition during androgen deprivation therapy for prostate cancer.
Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
[TBL] [Abstract][Full Text] [Related]
17. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer.
Chang D; Joseph DJ; Ebert MA; Galvão DA; Taaffe DR; Denham JW; Newton RU; Spry NA
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):223-8. PubMed ID: 24118850
[TBL] [Abstract][Full Text] [Related]
18. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
Cheung AS; Zajac JD; Grossmann M
Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
[TBL] [Abstract][Full Text] [Related]
19. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
20. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
